TBK1 and metabolic dysfunction-associated steatotic liver disease: As a dual inhibitor of TBK1 and IKK, AML has represented splendid curative effects that can even reverse the severity of NAFLD, and the TBK1-specific knockout in obese mice also brings about amelioration on metabolic disorders including lipid accumulation and inflammation (Reilly et al., 2013; Zhou et al., 2020).